Maxigen Biotech Inc. (TPE:1783)
Taiwan
· Delayed Price · Currency is TWD 39.40
+1.30 (3.41%)
Apr 29, 2026, 1:30 PM CST
Maxigen Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 811.56 | 680.65 | 622.12 | 604.43 | 511.98 | Upgrade
|
| Revenue | 811.56 | 680.65 | 622.12 | 604.43 | 511.98 | Upgrade
|
| Revenue Growth (YoY) | 19.23% | 9.41% | 2.93% | 18.06% | 11.86% | Upgrade
|
| Cost of Revenue | 247.84 | 197.33 | 198.02 | 230.44 | 250.95 | Upgrade
|
| Gross Profit | 563.72 | 483.33 | 424.09 | 373.99 | 261.03 | Upgrade
|
| Selling, General & Admin | 183.89 | 176.98 | 205.45 | 141.03 | 92.38 | Upgrade
|
| Research & Development | 126.11 | 111.97 | 68.6 | 99.63 | 75.68 | Upgrade
|
| Operating Expenses | 302.68 | 303.42 | 274.24 | 245.38 | 171.08 | Upgrade
|
| Operating Income | 261.04 | 179.91 | 149.85 | 128.62 | 89.95 | Upgrade
|
| Interest Expense | -0.04 | - | - | -0.07 | -0.2 | Upgrade
|
| Interest & Investment Income | 35.28 | 27.43 | 25.02 | 3.18 | 0.48 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.83 | 17.14 | 4 | 31.69 | -3.6 | Upgrade
|
| Other Non Operating Income (Expenses) | 4.78 | 1.05 | 0.66 | 1.08 | 10.84 | Upgrade
|
| EBT Excluding Unusual Items | 304.89 | 225.53 | 179.53 | 164.5 | 97.47 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 0.02 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0 | 13.62 | 1.03 | - | Upgrade
|
| Other Unusual Items | - | - | - | 0.26 | - | Upgrade
|
| Pretax Income | 304.89 | 225.55 | 193.14 | 165.78 | 97.47 | Upgrade
|
| Income Tax Expense | 39.58 | 35.38 | 27.31 | 26.38 | 9.8 | Upgrade
|
| Net Income | 265.31 | 190.17 | 165.83 | 139.4 | 87.67 | Upgrade
|
| Net Income to Common | 265.31 | 190.17 | 165.83 | 139.4 | 87.67 | Upgrade
|
| Net Income Growth | 39.52% | 14.68% | 18.95% | 59.01% | 38.47% | Upgrade
|
| Shares Outstanding (Basic) | 90 | 89 | 89 | 89 | 84 | Upgrade
|
| Shares Outstanding (Diluted) | 90 | 90 | 89 | 89 | 85 | Upgrade
|
| Shares Change (YoY) | 0.77% | 0.27% | 0.07% | 5.78% | 4.81% | Upgrade
|
| EPS (Basic) | 2.96 | 2.13 | 1.86 | 1.57 | 1.04 | Upgrade
|
| EPS (Diluted) | 2.94 | 2.12 | 1.85 | 1.56 | 1.04 | Upgrade
|
| EPS Growth | 38.68% | 14.59% | 18.59% | 50.28% | 31.75% | Upgrade
|
| Free Cash Flow | 208.36 | 266.45 | 148.76 | 254.05 | 103.34 | Upgrade
|
| Free Cash Flow Per Share | 2.31 | 2.97 | 1.66 | 2.84 | 1.22 | Upgrade
|
| Dividend Per Share | - | 0.830 | 1.000 | 0.476 | - | Upgrade
|
| Dividend Growth | - | -17.00% | 110.00% | - | - | Upgrade
|
| Gross Margin | 69.46% | 71.01% | 68.17% | 61.88% | 50.98% | Upgrade
|
| Operating Margin | 32.16% | 26.43% | 24.09% | 21.28% | 17.57% | Upgrade
|
| Profit Margin | 32.69% | 27.94% | 26.66% | 23.06% | 17.12% | Upgrade
|
| Free Cash Flow Margin | 25.67% | 39.15% | 23.91% | 42.03% | 20.18% | Upgrade
|
| EBITDA | 293.07 | 206.75 | 177.09 | 156.71 | 119.73 | Upgrade
|
| EBITDA Margin | 36.11% | 30.38% | 28.47% | 25.93% | 23.39% | Upgrade
|
| D&A For EBITDA | 32.03 | 26.85 | 27.24 | 28.09 | 29.79 | Upgrade
|
| EBIT | 261.04 | 179.91 | 149.85 | 128.62 | 89.95 | Upgrade
|
| EBIT Margin | 32.16% | 26.43% | 24.09% | 21.28% | 17.57% | Upgrade
|
| Effective Tax Rate | 12.98% | 15.69% | 14.14% | 15.91% | 10.05% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.